We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+9.23%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.19B
AUM Growth
+$35.3M
Cap. Flow
+$22.8M
Cap. Flow %
0.54%
Top 10 Hldgs %
34.58%
Holding
124
New
4
Increased
47
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$19.7M
2
RVMD icon
Revolution Medicines
RVMD
+$17.3M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$15.3M
4
PLRX icon
Pliant Therapeutics
PLRX
+$14M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.7M

Top Sells

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$58.6M
2
PEN icon
Penumbra
PEN
+$19.1M
3
IMCR icon
Immunocore
IMCR
+$18M
4
ALGN icon
Align Technology
ALGN
+$16.2M
5
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.08%
2 Consumer Staples 1.05%
3 Industrials 0.87%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCAT icon
76
Health Catalyst
HCAT
$131M
$10.9M 0.26%
929,900
– –
AURA icon
77
Aura Biosciences
AURA
$774M
$9.46M 0.23%
1,019,757
– –
BHVN icon
78
Biohaven
BHVN
$2.12B
$9.37M 0.22%
685,623
+16,710
+2% +$266K
VERV
79
DELISTED
Verve Therapeutics
VERV
$8.06M 0.19%
558,837
– –
MGNX icon
80
MacroGenics
MGNX
$260M
$8.05M 0.19%
1,123,096
– –
NVCR icon
81
NovoCure
NVCR
$2.04B
$7.52M 0.18%
125,000
– –
LUNG icon
82
Pulmonx
LUNG
$100M
$7.29M 0.17%
652,400
– –
OKUR
83
OnKure Therapeutics
OKUR
$166M
$6.84M 0.16%
114,319
– –
IRON icon
84
Disc Medicine
IRON
$3.05B
$6.64M 0.16%
313,468
-26,029
-8% -$580K
SPRB
85
Spruce Biosciences
SPRB
$128M
$6.03M 0.14%
36,375
+14,739
+68% +$2.74M
AUPH icon
86
Aurinia Pharmaceuticals
AUPH
$2.05B
$5.26M 0.13%
479,540
– –
ICVX
87
DELISTED
Icosavax, Inc. Common Stock
ICVX
$5.01M 0.12%
864,510
+83,510
+11% +$721K
GH icon
88
Guardant Health
GH
$22.4B
$4.69M 0.11%
200,000
– –
KNTE
89
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$4.67M 0.11%
746,973
– –
VIGL
90
DELISTED
Vigil Neuroscience
VIGL
$4.62M 0.11%
471,958
– –
XLO icon
91
Xilio Therapeutics
XLO
$60.5M
$4.57M 0.11%
102,911
+5,563
+6% +$244K
MREO
92
Mereo BioPharma
MREO
$54.8M
$4.41M 0.11%
6,244,897
– –
PRTK
93
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.4M 0.11%
1,734,037
– –
NVTA
94
DELISTED
Invitae Corporation
NVTA
$4.38M 0.1%
3,241,425
+143,900
+5% +$283K
THRX
95
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$3.88M 0.09%
437,329
– –
NVAX icon
96
Novavax
NVAX
$1.3B
$3.71M 0.09%
535,400
+2,800
+0.5% +$25.8K
FATE icon
97
Fate Therapeutics
FATE
$322M
$3.49M 0.08%
612,215
+502,215
+457% +$3.03M
BEAM icon
98
Beam Therapeutics
BEAM
$2.79B
$3.41M 0.08%
111,430
– –
ADAP
99
DELISTED
Adaptimmune Therapeutics
ADAP
$3.04M 0.07%
2,787,845
+111,309
+4% +$172K
DSGN icon
100
Design Therapeutics
DSGN
$899M
$2.66M 0.06%
460,391
– –
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Rock Springs Capital Management held 124 positions worth $4.19B, up 0.85% from $4.16B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management's Q1 2023 filing shows 4 new, 47 increased, 8 reduced and 3 closed positions. Its largest new stake was Mineralys Therapeutics: 1,167,492 shares worth $18.3M. The largest sale was Baxter International, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2023 buy was Mineralys Therapeutics: 1,167,492 shares worth $18.3M.
  • Rock Springs Capital Management added most to Karuna Therapeutics, Inc. Common Stock in Q1 2023, an estimated $15.3M increase.
  • Rock Springs Capital Management's biggest Q1 2023 reduction was Penumbra, cutting an estimated $19.1M.
  • Rock Springs Capital Management fully exited Baxter International in Q1 2023, selling an estimated $58.6M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $4.19B portfolio in Q1 2023.
  • Rock Springs Capital Management opened 4 new positions and closed 3 in Q1 2023.
  • Rock Springs Capital Management's portfolio value rose 0.85% quarter-over-quarter to $4.19B.

Based on Rock Springs Capital Management's 13F filing for Q1 2023, filed 15 May 2023.